The treatment modalities for painful diabetic peripheral neuropathy (PDPN) include antidepressants, anticonvulsants, capsaicin, membrane stabilizers and analgesics. Recent guidelines recommend pregabalin as a first line treatment for PDPN. But controversy exists about its efficacy and safety. The main objective of the study is to determine the safety, efficacy of pregabalin treatment for PDPN. An interventional cohort study was carried out in a tertiary care teaching hospital. Subjects who satisfy the inclusion criteria were included in the study after obtaining written informed consent. A total of 52 subjects were enrolled in the study. PDPN was confirmed by means of (1) Diabetic neuropathy symptom (DNS) score of more than one point, (2) Diabetic neuropathy examination score (DNE) of more than three points, (3) Neuropathic disability score (NDS) of more than 6 points and (4) Pain of more than 50% assessed by Visual Analog Scale (VAS). The subjects received pregabalin 75mg once daily for one week followed by 75 mg twice daily for further 3 weeks based on patient’s tolerability. Pain intensity was measured by using Short-Form McGill pain questionnaire. Safety of therapy was assessed from the incidence of adverse events including physical as well as laboratory evaluations. All study subjects’s enrolled received pregabalin. Study showed that pregabalin treatment significantly reduced pain in diabetic peripheral neuropathy with mean pain score 11.52 ± 9.30 (P value 0.00). The most common adverse effects of pregabalin were dizziness, peripheral edema, and somnolence. The study concluded that pregabalin significantly reduces pain and improve quality of life in PDPN.There was a dose-related increase in efficacy of pregabalin treatment. Moreover, there was a dose-related increase in incidence of most adverse events which are generally mild to moderate. Disclosure C. Radhakrishnan: None. A. Ut: None. S. K: None. N. Manikath: None. R.R. Cr: None.
Diabetic neuropathy is one of the most common complication of diabetes mellitus. Many studies had reported that type 2 diabetes mellitus increases the risk of cognitive impairement,depression and sleep impairement in patients with diabetes mellitus. The main objective of the study is to determine whether any significant impairement in cognition function, sleep quality and depression status exist among diabetic neuropathy patients compared to patients with type 2 diabetes mellitus alone. A prospective observational study was conducted in a tertiary care teaching hospital. Patients who satisfied both inclusion and exclusion criteria were included in the study. A total of 59 type 2 diabetes mellitus patients with neuropathy and 55 patients with out neuropathy were enrolled in to the study after obtaining written informed consent. Cognitive status was assessed with the help of MOCA questionnaire. Sleep quality was assessed by using pittsburgh sleep quality index questionnare and depression, by using PHQ-9 questionnaire. The diabetic neuropathic patients showed a significant impairement in cognitive status (P value 0.003), sleep quality (P value 0.000) and depression status (p value 0.000). The study concluded that diabetic neuropathy increases the risk of cognitive impairement, impairement in sleep quality and depression in type 2 diabetes mellitus patients. Disclosure C. Radhakrishnan: None. R.R. Cr: None. S. K: None. A. Ut: None.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.